Thromboxane A2 receptor (TP) and Prostacyclin receptor (IP) (TP (Thromboxane receptor), IP (Prostacyclin receptor))

Thromboxane–prostacyclin balance modulation refers to the regulation of the equilibrium between thromboxane A2 (TXA2) and prostacyclin (PGI2) signaling in the vasculature. It is not a single molecular entity or receptor, but describes a critical physiological axis involving two opposing eicosanoid pathways that affect vascular homeostasis and platelet activity. The canonical names for the principal targets are Thromboxane A2 receptor (TP) and Prostacyclin receptor (IP), both belonging to the prostanoid (prostaglandin) receptor family, which are class A G protein-coupled receptors (GPCRs). Thromboxane A2 is produced by platelets and acts via the thromboxane receptor (TP) to promote vasoconstriction and platelet aggregation, thus supporting hemostasis ("clotting") and thrombosis. Prostacyclin is secreted by vascular endothelial cells and activates the prostacyclin receptor (IP), causing vasodilation and inhibiting platelet aggregation ("anti-clotting"). Proper physiological function relies on a *dynamic balance* between these antagonistic pathways; disruption of this balance can result in bleeding disorders (excess prostacyclin) or thrombotic events (excess thromboxane). In summary, "Thromboxane–prostacyclin balance modulation" should be mapped to the Thromboxane A2 receptor (TP) and Prostacyclin receptor (IP), two GPCRs that mediate clinically relevant and opposing effects on vasculature and coagulation. Modulating this axis is a validated therapeutic strategy in cardiovascular disease and thrombosis; direct molecular target information should refer to these specific receptors. The original entry is not a correct molecular target, but describes a process involving well-characterized receptors.

Other names

Thromboxane receptorTBXA2RTXA2 receptorProstacyclin receptorPGI2 receptorPTGIR

TP antagonists: block thromboxane-mediated vasoconstriction and platelet aggregation. IP agonists: promote vasodilation, inhibit platelet aggregation. COX inhibitors (aspirin/NSAIDs): block precursor synthesis for both PGI2 and TXA2, but low-dose aspirin preferentially affects TXA2.